Novo Nordisk Tries to Snatch a Weight-Loss Biotech From Pfizer. There Are Political Risks. Denmark’s Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on ...
StockStory.org on MSN
Winners And Losers Of Q3: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks
Looking back on patient monitoring stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including DexCom ...
DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is ...
Morgan Stanley lowered the firm’s price target on DexCom (DXCM) to $63 from $89 and keeps an Overweight rating on the shares. Published first on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback